• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ispire Technology Inc. Reports Financial Results for the Fiscal Year 2025

    9/16/25 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ISPR alert in real time by email

    LOS ANGELES, Sept. 16, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported results for the fiscal year 2025, which ended on June 30, 2025.

    Ispire

    Fiscal Year 2025 Financial Results

    • Revenue decreased to $127.5 million, compared to $151.9 million in the 2024 fiscal year.
    • Gross profit declined to $22.6 million, as compared to $29.8 million in the 2024 fiscal year.
    • Gross margin decreased to 17.8%, as compared to 19.6% in the 2024 fiscal year.
    • Total operating expenses increased to $60.5 million, compared to $43.7 million in the 2024 fiscal year.
    • Accounts receivable, net decreased by 21% from $59.7 million in fiscal 2024 to $47.0 million in fiscal 2025.
    • Net loss of $39.2 million, compared to net loss of $14.8 million in the 2024 fiscal year.

    Michael Wang, Co-Chief Executive Officer of Ispire, commented, "Fiscal year 2025 marked a pivotal period in Ispire's strategic transformation, as we continued to shift away from the cannabis industry toward the higher-value nicotine sector. We made the intentional strategic decision to focus on quality customers versus quantity, prioritizing long-term partnerships as we repositioned our business for sustainable growth. Our investments in breakthrough technologies including IKE Tech LLC and our G-Mesh technology, are gaining significant traction with major tobacco companies as these innovations move through the regulatory approval process."

    "We continued advancing our PMTA activities while awaiting updates on the groundbreaking component PMTA submission filed by our strategic joint venture, IKE Tech LLC, which represents blockchain-based age verification technology that could fundamentally transform the regulatory landscape for nicotine delivery systems. We are also progressing preparations for comprehensive PMTA submissions for flavored ENDS products. These products will feature integrated IKE Tech age-verification technology, with our initial filing strategy focusing on four distinct flavored offerings, addressing a critical gap in today's marketplace. Lastly, our international nicotine ODM business represents a key growth opportunity that is now gaining significant momentum after a slower than expected start. Coming into fiscal Q1 2026, we were at $18M in backlog orders. These strategic initiatives have positioned Ispire to capitalize on the growing global demand for precision vaping technology, while maintaining our commitment to responsible product development," Mr. Wang concluded.

    Jay Yu, Chief Financial Officer of Ispire, added, "Ispire has focused on streamlining our operations and cut expenses across the business, with optimization measures reducing annual payroll by a total estimated annual savings of $10.2 million. General and administrative expenses declined year over year, from $31.1 million for the year ended June 30, 2024, to $30.0 million for the year ended June 30, 2025, while net loss was widened by $24.5 million year-over-year. We remain focused on strengthening collections and enhancing customer quality. Management believes these disciplined actions position Ispire for sustainable, long-term growth."

    Financial Results for the Fiscal Year Ended June 30, 2025

    For the fiscal year ended June 30, 2025, Ispire reported revenue of $127.5 million compared to $151.9 million during fiscal 2024. The decrease in revenue was primarily due to realignment of our business towards nicotine, while moving away from cannabis customers, which the Company believes will deliver improved accounts receivable and more sustainable long-term growth.

    Gross profit for the fiscal year ended June 30, 2025, was $22.6 million compared to $29.8 million for the same period in fiscal year 2024. Over fiscal 2025, gross margin decreased to 17.8%, from 19.6%. The decrease in gross profit and gross margin was primarily due to the strategic repositioning away from cannabis which led to the revenue reduction for this period.

    Total operating expenses for the fiscal year ended June 30, 2025 were $60.5 million as compared to $43.7 million in the same period in fiscal year 2024. This increase was largely due to a rise in sales and marketing expenses with a ramp up of marketing activities, as well as an increase in expected credit loss on accounts receivables, offset by a decrease in stock based compensation expenses due to cutting headcount in streamlining North American operations and a reduction in R&D expenses.

    For the fiscal year ended June 30, 2025, net loss was $39.2 million or $0.69 per share, compared to a net loss of $14.8 million, or $0.27 per share for fiscal year 2024.

    As of June 30, 2025, Ispire had $24.4 million in cash and cash equivalents and working capital of $0.4 million.

    Conference Call

    The Company will conduct a conference call at 8:00 am Eastern Time on Tuesday, September 16, 2025, to discuss the results. Ispire management will host the conference call, followed by a question-and-answer period.

    Please call the conference call dial-in 5-10 minutes prior to the start time and ask for the "Ispire Technology Call." An operator will register your name and organization.

    • Date: Tuesday, September 16, 2025
    • Time: 8:00 am ET
    • Dial-In Numbers: North America 877-451-6152 or International +1 201-389-0879

    This conference call will be broadcast live on the Internet and can be accessed by all interested parties at https://viavid.webcasts.com/starthere.jsp?ei=1730055&tp_key=20c725b587.

    Please access the link at least fifteen minutes prior to the start of the call to register, download, and install any necessary audio software.

    A playback will be available until 12:00 midnight Eastern Time on Tuesday, September 30, 2025. To listen, please dial 844-512-2921 or +1 412-317-6671. Use the passcode 13755309 to access the replay.

    About Ispire Technology Inc.

    Ispire is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The Company's operating subsidiaries own or license more than 200 patents received or filed globally. Ispire's tobacco products are marketed under the Aspire brand name and are sold worldwide (except in the U.S., People's Republic of China and Russia) primarily through its global distribution network. The Company's cannabis products are marketed under the Ispire brand name primarily on an original design manufacturer (ODM) basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware mainly in the U.S., and it recently commenced its marketing activities in Canada and Europe. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube. Any information contained on, or that can be accessed through, the Company's website, any other website or any social media, is not a part of this press release.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company will be successful in its plans to further expand into the African market; whether the Company's joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the "Joint Venture") may be successful in achieving its goals as currently contemplated, with different terms, or at all; the Joint Venture's ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company's ability to collect its accounts receivable in a timely manner; the Company's business strategies; the ability of the Company to market to the Ispire ONE™; Ispire ONE™'s success in meeting its goals; the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe; and the risk and uncertainties described in "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Cautionary Note on Forward-Looking Statements" and the additional risk described in Ispire's Annual Report on Form 10-K for the year ended June 30, 2024 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

     

    ISPIRE TECHNOLOGY INC.

    CONSOLIDATED BALANCE SHEETS

    (In $USD, except share and per share data)

    ‌





    June 30,





    2025





    2024

    Assets











    Current assets:











    Cash



    $

    24,351,765





    $

    35,071,294

    Accounts receivable, net





    39,664,145







    59,734,765

    Inventories, net





    6,647,970







    6,365,394

    Prepaid expenses and other current assets





    2,244,505







    1,400,152

    Total current assets





    72,908,385







    102,571,605

    Other assets:















    Accounts receivable – non current





    7,367,158







    -

    Property, plant and equipment, net





    2,952,800







    2,582,457

    Intangible assets, net





    2,232,620







    1,375,666

    Right-of-use assets – operating leases





    5,030,005







    3,579,140

    Other investment





    2,000,000







    2,000,000

    Equity method investment





    9,515,546







    10,248,048

    Other non-current assets





    210,617







    284,050

    Total other assets





    29,308,746







    20,069,361

    Total assets



    $

    102,217,131





    $

    122,640,966

    Liabilities and stockholders' equity















    Current liabilities















    Accounts payable



    $

    4,172,476





    $

    3,779,723

    Accounts payable – related party





    52,420,256







    67,046,472

    Contract liabilities





    4,861,250







    2,218,166

    Accrued liabilities and other payables





    8,099,991







    11,738,339

    Borrowing – current portion





    1,146,766







    -

    Operating lease liabilities – current portion





    1,838,815







    1,207,832

    Total current liabilities





    72,539,554







    85,990,532

    ‌















    Other liabilities:















    Amount due to a related party





    25,000,000







    -

    Borrowing – net of current portion





    805,361







    -

    Operating lease liabilities – net of current portion





    3,267,522







    2,194,094

    Total liabilities





    101,612,437







    88,184,626

    ‌















    Commitments and contingencies















    ‌















    Stockholders' equity:















    Common stock, par value $0.0001 per share; 140,000,000 shares authorized;

      57,193,734 and 56,470,636 shares issued and outstanding as of June 30, 2025

      and June 30, 2024





    5,719







    5,647

    Treasury stock, at cost





    (60,488)







    -

    Additional paid-in capital





    48,833,601







    43,217,391

    Accumulated deficit





    (48,065,267)







    (8,825,041)

    Accumulated other comprehensive (loss)/income





    (108,871)







    58,343

    Total stockholders' equity





    604,694







    34,456,340

    Total liabilities and stockholders' equity



    $

    102,217,131





    $

    122,640,966

     

    ISPIRE TECHNOLOGY INC.

    CONSOLIDATED STATEMENTS OF OPERATIONS AND

    COMPREHENSIVE LOSS

    (In $USD, except share and per share data)

    ‌





    Years ended June 30,





    2025





    2024





    ‌







    Revenue



    $

    127,494,304





    $

    151,908,691

    Cost of revenue





    104,844,633







    122,126,245

    Gross profit





    22,649,671







    29,782,446

    Operating expenses:















    Sales and marketing expenses





    8,439,384







    6,608,724

    Credit loss expenses





    22,034,812







    6,015,752

    General and administrative expenses





    30,025,334







    31,052,109

    Total operating expenses





    60,499,530







    43,676,585

    Loss from operations





    (37,849,859)







    (13,894,139)

    Other income (expense):















    Interest income, net





    86,996







    365,251

    Exchange loss, net





    (86,570)







    (70,293)

    Other (expense) income, net





    (187,089)







    113,405

    Total other (expense) income, net





    (186,663)







    408,363

    Loss before income taxes





    (38,036,522)







    (13,485,776)

    Income taxes – current





    (1,203,704)







    (1,282,046)

    Net loss



    $

    (39,240,226)





    $

    (14,767,822)

    Other comprehensive (loss) income















    Foreign currency translation adjustments





    (167,214)







    222,111

    Comprehensive loss





    (39,407,440)







    (14,545,711)

    Net loss per share















    Basic and diluted



    $

    (0.69)





    $

    (0.27)

    Weighted average shares outstanding:















    Basic and diluted





    56,853,552







    54,812,900

     

    For more information, kindly contact:

    IR Contact:

    KCSA Strategic Communications

    Phil Carlson

    212-896-1233

    [email protected] 



    PR Contact:

    Ellen Mellody

    570-209-2947

    [email protected] 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ispire-technology-inc-reports-financial-results-for-the-fiscal-year-2025-302556911.html

    SOURCE Ispire Technology Inc.

    Get the next $ISPR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISPR

    DatePrice TargetRatingAnalyst
    5/20/2024$11.00Buy
    ROTH MKM
    More analyst ratings

    $ISPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CLO and Secretary Pryzbyla Steven P. sold $45,001 worth of shares (17,046 units at $2.64), decreasing direct ownership by 4% to 399,664 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    10/2/25 4:30:03 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Cox Brent was granted 29,784 shares, increasing direct ownership by 142% to 50,782 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    7/11/25 4:31:16 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Burch Christopher Robert was granted 27,178 shares, increasing direct ownership by 188% to 41,658 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    7/11/25 4:30:47 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ispire Technology Inc. Reports Financial Results for the Fiscal Year 2025

    LOS ANGELES, Sept. 16, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported results for the fiscal year 2025, which ended on June 30, 2025. Fiscal Year 2025 Financial Results Revenue decreased to $127.5 million, compared to $151.9 million in the 2024 fiscal year.Gross profit declined to $22.6 million, as compared to $29.8 million in the 2024 fiscal year.Gross margin decreased to 17.8%, as compared to 19.6% in the 2024 fiscal year.Total operating expenses

    9/16/25 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal Fourth Quarter and Full Year 2025 Earnings Conference Call

    LOS ANGELES, Sept. 12, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") ((ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00am ET on Tuesday, September 16, 2025, to discuss the Company's financial results for its fiscal fourth quarter and full year ended June 30, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Tuesday, September 16, 2025Time: 8:00am ETDial

    9/12/25 4:05:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire-Backed IKE Tech to Spotlight Breakthroughs in Vape Safety and Harm Reduction at World Vape Show Dubai

    President of Ike Tech and SVP of International Nicotine at Ispire, John Patterson, to Join Global Leaders on Industry Innovation Panel LOS ANGELES, June 16, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a global leader in vaporization technology and precision dosing, announced its joint venture IKE Tech LLC ("IKE Tech") will spotlight Ike Tech's blockchain based point of use age-gating and Smart-Tag authentication technologies at the World Vape Show Dubai, June 18–20, 2025. John Patterson, president of Ike Tech and senior vice president of International Nicotine at Ispire, will be featured on a high-level panel titled "Innovations in Consumer Safety

    6/16/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Ispire Technology with a new price target

    ROTH MKM initiated coverage of Ispire Technology with a rating of Buy and set a new price target of $11.00

    5/20/24 7:18:59 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    SEC Filings

    View All

    SEC Form 10-K filed by Ispire Technology Inc.

    10-K - Ispire Technology Inc. (0001948455) (Filer)

    9/15/25 4:06:16 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Ispire Technology Inc. (0001948455) (Filer)

    6/26/25 4:30:08 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Ispire Technology Inc. (0001948455) (Filer)

    5/23/25 4:30:34 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Financials

    Live finance-specific insights

    View All

    Ispire Technology Inc. Reports Financial Results for the Fiscal Year 2025

    LOS ANGELES, Sept. 16, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported results for the fiscal year 2025, which ended on June 30, 2025. Fiscal Year 2025 Financial Results Revenue decreased to $127.5 million, compared to $151.9 million in the 2024 fiscal year.Gross profit declined to $22.6 million, as compared to $29.8 million in the 2024 fiscal year.Gross margin decreased to 17.8%, as compared to 19.6% in the 2024 fiscal year.Total operating expenses

    9/16/25 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal Fourth Quarter and Full Year 2025 Earnings Conference Call

    LOS ANGELES, Sept. 12, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") ((ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00am ET on Tuesday, September 16, 2025, to discuss the Company's financial results for its fiscal fourth quarter and full year ended June 30, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Tuesday, September 16, 2025Time: 8:00am ETDial

    9/12/25 4:05:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2025

    Accounts Receivable Decreased from $67.7M to $60.4M Improving Company Financial PositionPost-Quarter End, IKE Tech Filed PMTA with the FDA for its Age-Gating Joint Venture Component with IKELaunched SproutTM in Collaboration with Raw Garden, an Advanced All-In-One Cannabis Vapor Device Ensuring Purity and Safety  LOS ANGELES, May 12, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2025, for the three months ending March 31, 2025. Fiscal Third Quarter 2025 Financial Results Revenue of $26.2 million versus $30.0 mil

    5/12/25 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Leadership Updates

    Live Leadership Updates

    View All

    Ispire-Backed IKE Tech to Spotlight Breakthroughs in Vape Safety and Harm Reduction at World Vape Show Dubai

    President of Ike Tech and SVP of International Nicotine at Ispire, John Patterson, to Join Global Leaders on Industry Innovation Panel LOS ANGELES, June 16, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a global leader in vaporization technology and precision dosing, announced its joint venture IKE Tech LLC ("IKE Tech") will spotlight Ike Tech's blockchain based point of use age-gating and Smart-Tag authentication technologies at the World Vape Show Dubai, June 18–20, 2025. John Patterson, president of Ike Tech and senior vice president of International Nicotine at Ispire, will be featured on a high-level panel titled "Innovations in Consumer Safety

    6/16/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

    Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

    5/15/25 4:30:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Announces Key Leadership Appointments

    LOS ANGELES, Aug. 14, 2023 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or "the Company") (NASDAQ:ISPR), a leader in vapor technology, providing high-quality, innovative products with first-class performance, announced today the appointment of Michael Wang as its Co-Chief Executive Officer.  Mr. Wang previously served as Chief Financial Officer. Concurrently, Daniel J. Machock was appointed as the new Chief Financial Officer. Mr. Wang has assumed the role of Co-Chief Executive Officer alongside Tuanfang Liu, as Co-Chief Executive Officer. This strengthened leadership structure is designed to refine Ispire's strategic direction and spearhead the Company's future growth. Ispire's decision

    8/14/23 8:35:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ispire Technology Inc.

    SC 13G - Ispire Technology Inc. (0001948455) (Subject)

    7/12/24 5:00:02 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care